RB1 and osteosarcoma: Ren et al. carried out a systematic review that included 12 studies with a total of 491 patients; alterations in Rb1 were associated with higher mortality, a higher risk of metastatic disease and worse response to chemotherapy treatment in patients with osteosarcoma [34].